Published in Biotech Business Week, December 20th, 2004
"The antipsychotic efficacy of aripiprazole is not generally associated with extrapyramidal symptoms, cardiovascular effects, sedation or elevations in serum protactin that characterize typical or atypical antipsychotics," scientists in Japan explained.
T. Hirose and colleagues at Otsuka Pharmaceutical Co., Ltd. conducted a study "to clarify the mechanism of action of aripiprazole that underlies its favorable clinical profiles."
"The preclinical efficacy and side-effect profiles of aripiprazole were evaluated using several pharmaco-behavioral test systems in mice and rats,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.